• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

组蛋白去乙酰化酶抑制剂的锌结合基团。

Zinc binding groups for histone deacetylase inhibitors.

作者信息

Zhang Lei, Zhang Jian, Jiang Qixiao, Zhang Li, Song Weiguo

机构信息

a Department of Medicinal Chemistry, School of Pharmacy , Weifang Medical University , Weifang , Shandong , China.

b School of Pharmacy , Qingdao University , Qingdao , Shandong , China.

出版信息

J Enzyme Inhib Med Chem. 2018 Dec;33(1):714-721. doi: 10.1080/14756366.2017.1417274.

DOI:10.1080/14756366.2017.1417274
PMID:29616828
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6009916/
Abstract

Zinc binding groups (ZBGs) play a crucial role in targeting histone deacetylase inhibitors (HDACIs) to the active site of histone deacetylases (HDACs), thus determining the potency of HDACIs. Due to the high affinity to the zinc ion, hydroxamic acid is the most commonly used ZBG in the structure of HDACs. An alternative ZBG is benzamide group, which features excellent inhibitory selectivity for class I HDACs. Various ZBGs have been designed and tested to improve the activity and selectivity of HDACIs, and to overcome the pharmacokinetic limitations of current HDACIs. Herein, different kinds of ZBGs are reviewed and their features have been discussed for further design of HDACIs.

摘要

锌结合基团(ZBGs)在将组蛋白去乙酰化酶抑制剂(HDACIs)靶向至组蛋白去乙酰化酶(HDACs)的活性位点方面发挥着关键作用,从而决定了HDACIs的效力。由于对锌离子具有高亲和力,异羟肟酸是HDACs结构中最常用的ZBG。另一种ZBG是苯甲酰胺基团,其对I类HDACs具有出色的抑制选择性。已经设计并测试了各种ZBG,以提高HDACIs的活性和选择性,并克服当前HDACIs的药代动力学限制。在此,对不同种类的ZBG进行了综述,并讨论了它们的特征,以便进一步设计HDACIs。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2a7/6009916/b804f9d6c677/IENZ_A_1417274_F0006_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2a7/6009916/ea9e8682172b/IENZ_A_1417274_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2a7/6009916/aab511b0ab59/IENZ_A_1417274_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2a7/6009916/ea318344edec/IENZ_A_1417274_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2a7/6009916/907492ac8187/IENZ_A_1417274_F0004_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2a7/6009916/afa25873273a/IENZ_A_1417274_F0005_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2a7/6009916/b804f9d6c677/IENZ_A_1417274_F0006_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2a7/6009916/ea9e8682172b/IENZ_A_1417274_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2a7/6009916/aab511b0ab59/IENZ_A_1417274_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2a7/6009916/ea318344edec/IENZ_A_1417274_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2a7/6009916/907492ac8187/IENZ_A_1417274_F0004_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2a7/6009916/afa25873273a/IENZ_A_1417274_F0005_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2a7/6009916/b804f9d6c677/IENZ_A_1417274_F0006_B.jpg

相似文献

1
Zinc binding groups for histone deacetylase inhibitors.组蛋白去乙酰化酶抑制剂的锌结合基团。
J Enzyme Inhib Med Chem. 2018 Dec;33(1):714-721. doi: 10.1080/14756366.2017.1417274.
2
Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.三种锌结合基团的 HDAC 抑制剂比较 - 效力、选择性和酶动力学研究。
Bioorg Med Chem Lett. 2022 Aug 15;70:128797. doi: 10.1016/j.bmcl.2022.128797. Epub 2022 May 14.
3
Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases.非羟肟酸锌结合基团作为组蛋白去乙酰化酶的弹头。
Molecules. 2021 Aug 25;26(17):5151. doi: 10.3390/molecules26175151.
4
The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs.锌结合基团效应:非羟肟酸伏立诺他类似物的启示。
J Med Chem. 2023 Jun 22;66(12):7698-7729. doi: 10.1021/acs.jmedchem.3c00226. Epub 2023 Jun 5.
5
Computational exploration of zinc binding groups for HDAC inhibition.计算探索组锌结合的 HDAC 抑制。
J Org Chem. 2013 May 17;78(10):5051-5. doi: 10.1021/jo400406g. Epub 2013 Apr 29.
6
An efficient synthesis of SK-658 and its analogs as potent histone deacetylase inhibitors.高效合成SK-658及其类似物作为强效组蛋白去乙酰化酶抑制剂。
Bioorg Chem. 2015 Apr;59:145-50. doi: 10.1016/j.bioorg.2015.02.009. Epub 2015 Mar 7.
7
Investigation on the ZBG-functionality of phenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase inhibitors.苯基-4-基-丙烯酰氧肟酸衍生物作为组蛋白脱乙酰酶抑制剂的ZBG功能研究。
Bioorg Med Chem Lett. 2015 Oct 15;25(20):4457-60. doi: 10.1016/j.bmcl.2015.09.006. Epub 2015 Sep 5.
8
Hydrazides as Inhibitors of Histone Deacetylases.酰腙类化合物作为组蛋白去乙酰化酶抑制剂
J Med Chem. 2024 Aug 22;67(16):13512-13533. doi: 10.1021/acs.jmedchem.4c00541. Epub 2024 Aug 2.
9
Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors--What Some May Have Forgotten or Would Rather Forget?为何异羟肟酸酯可能并非最佳的组蛋白去乙酰化酶抑制剂——有些人可能遗忘或宁愿忘却的是什么?
ChemMedChem. 2016 Jan 5;11(1):15-21. doi: 10.1002/cmdc.201500486. Epub 2015 Nov 25.
10
Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.苯甲脒基类组蛋白去乙酰化酶抑制剂的合成与应用。
Eur J Med Chem. 2017 Jul 28;135:174-195. doi: 10.1016/j.ejmech.2017.04.013. Epub 2017 Apr 10.

引用本文的文献

1
Recent Insights into the Creation of Histone Deacetylase Inhibitors for the Treatment of Human Diseases.用于治疗人类疾病的组蛋白去乙酰化酶抑制剂创制的最新见解
Int J Mol Sci. 2025 Sep 4;26(17):8629. doi: 10.3390/ijms26178629.
2
Targeting neuroblastoma with hydroxamic acid based HDAC1 and HDAC2 inhibitors: Insights from in vitro and in vivo studies.基于异羟肟酸的HDAC1和HDAC2抑制剂靶向神经母细胞瘤:来自体外和体内研究的见解
Invest New Drugs. 2025 Jul 10. doi: 10.1007/s10637-025-01559-y.
3
Advancements in Hydrazide-Based HDAC Inhibitors: A Review of Recent Developments and Therapeutic Potential.

本文引用的文献

1
Synthesis of ST7612AA1, a Novel Oral HDAC Inhibitor, via Radical 
Thioacetic Acid Addition.通过自由基硫代乙酸加成法合成新型口服组蛋白去乙酰化酶抑制剂ST7612AA1
Curr Bioact Compd. 2016 Dec;12(4):282-288. doi: 10.2174/1573407212666160504160556.
2
Potent and Selective Non-hydroxamate Histone Deacetylase 8 Inhibitors.强效且选择性的非羟肟酸类组蛋白去乙酰化酶 8 抑制剂。
ChemMedChem. 2016 Dec 6;11(23):2598-2606. doi: 10.1002/cmdc.201600528. Epub 2016 Nov 9.
3
Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia.
基于酰肼的组蛋白去乙酰化酶抑制剂的研究进展:近期发展与治疗潜力综述
J Med Chem. 2025 Jul 24;68(14):14171-14194. doi: 10.1021/acs.jmedchem.5c01677. Epub 2025 Jul 10.
4
Development of novel benzamide class I selective lysine deacetylase inhibitors as potent anticancer agents.新型苯甲酰胺类 I 型选择性赖氨酸脱乙酰酶抑制剂作为强效抗癌剂的研发
J Enzyme Inhib Med Chem. 2025 Dec;40(1):2520612. doi: 10.1080/14756366.2025.2520612. Epub 2025 Jul 1.
5
Drug Discovery for Histone Deacetylase Inhibition: Past, Present and Future of Zinc-Binding Groups.组蛋白去乙酰化酶抑制作用的药物发现:锌结合基团的过去、现在与未来
Pharmaceuticals (Basel). 2025 Apr 16;18(4):577. doi: 10.3390/ph18040577.
6
Computationally Guided Design, Synthesis, and Evaluation of Novel Non-Hydroxamic Histone Deacetylase Inhibitors, Based on -Trifluoroacetamide as a Zinc-Binding Group, Against Breast Cancer.基于三氟乙酰胺作为锌结合基团的新型非异羟肟酸类组蛋白去乙酰化酶抑制剂的计算辅助设计、合成及对乳腺癌的评估
Pharmaceuticals (Basel). 2025 Feb 28;18(3):351. doi: 10.3390/ph18030351.
7
Enhancing HDAC Inhibitor Screening: Addressing Zinc Parameterization and Ligand Protonation in Docking Studies.增强组蛋白去乙酰化酶抑制剂筛选:解决对接研究中的锌参数化和配体质子化问题。
Int J Mol Sci. 2025 Jan 20;26(2):850. doi: 10.3390/ijms26020850.
8
HDAC4/5 Inhibitor, LMK-235 Improves Animal Voluntary Movement in MPTP-Induced Parkinson's Disease Model.HDAC4/5抑制剂LMK-235改善MPTP诱导的帕金森病模型动物的自主运动。
Pharmacol Res Perspect. 2025 Feb;13(1):e70057. doi: 10.1002/prp2.70057.
9
Design, synthesis, biological and evaluation of 3‑carboxy‑coumarin sulfonamides as potential antiproliferative agents targeting HDAC6.作为靶向HDAC6的潜在抗增殖剂的3-羧基香豆素磺酰胺的设计、合成、生物学研究及评价
Biomed Rep. 2024 Oct 30;22(1):6. doi: 10.3892/br.2024.1884. eCollection 2025 Jan.
10
The Circulating Methylome in Childhood-Onset Inflammatory Bowel Disease.儿童期起病的炎症性肠病中的循环甲基化组
J Crohns Colitis. 2025 Mar 5;19(3). doi: 10.1093/ecco-jcc/jjae157.
用于急性髓系白血病的含变构酰肼的I类组蛋白去乙酰化酶抑制剂的研发
J Med Chem. 2016 Nov 10;59(21):9942-9959. doi: 10.1021/acs.jmedchem.6b01385. Epub 2016 Oct 26.
4
Histone deacetylase inhibitors as cancer therapeutics.组蛋白去乙酰化酶抑制剂作为癌症治疗药物。
Ann Transl Med. 2016 Aug;4(15):287. doi: 10.21037/atm.2016.07.22.
5
Inside HDACs with more selective HDAC inhibitors.与更具选择性的组蛋白去乙酰化酶(HDAC)抑制剂相关的组蛋白去乙酰化酶研究进展
Eur J Med Chem. 2016 Oct 4;121:451-483. doi: 10.1016/j.ejmech.2016.05.047. Epub 2016 May 25.
6
Inhibitors of histone deacetylase as antitumor agents: A critical review.组蛋白去乙酰化酶抑制剂作为抗肿瘤药物的综述:批判性评价
Bioorg Chem. 2016 Aug;67:18-42. doi: 10.1016/j.bioorg.2016.05.005. Epub 2016 May 17.
7
Novel thiol-based histone deacetylase inhibitors bearing 3-phenyl-1H-pyrazole-5-carboxamide scaffold as surface recognition motif: Design, synthesis and SAR study.以3-苯基-1H-吡唑-5-甲酰胺支架为表面识别基序的新型基于硫醇的组蛋白脱乙酰酶抑制剂:设计、合成及构效关系研究
Bioorg Med Chem Lett. 2016 Jan 15;26(2):375-379. doi: 10.1016/j.bmcl.2015.12.007. Epub 2015 Dec 7.
8
Investigation on the ZBG-functionality of phenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase inhibitors.苯基-4-基-丙烯酰氧肟酸衍生物作为组蛋白脱乙酰酶抑制剂的ZBG功能研究。
Bioorg Med Chem Lett. 2015 Oct 15;25(20):4457-60. doi: 10.1016/j.bmcl.2015.09.006. Epub 2015 Sep 5.
9
A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.同步放疗、替莫唑胺与组蛋白去乙酰化酶抑制剂丙戊酸治疗胶质母细胞瘤患者的2期研究。
Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):986-992. doi: 10.1016/j.ijrobp.2015.04.038. Epub 2015 Apr 30.
10
HDAC8: a multifaceted target for therapeutic interventions.HDAC8:治疗干预的多面向靶标。
Trends Pharmacol Sci. 2015 Jul;36(7):481-92. doi: 10.1016/j.tips.2015.04.013. Epub 2015 May 23.